Logo
Genetiq SLU-PP-332
Genetiq SLU-PP-332 - Image 2
,

Genetiq SLU-PP-332

£74.00

Out of stock

Categories: ,

GenetiQ SLU-PP-332 (100 × 250 mg Tablets)

Description:

SLU-PP-332 is an orally available experimental small molecule that has gained interest in preclinical research for its potential role in modulating energy metabolism, mitochondrial activity, and metabolic efficiency. It is currently being investigated in laboratory studies for its ability to influence pathways related to fat oxidation, endurance, and cellular energy balance.

Research Background:

Initial studies suggest SLU-PP-332 may act on PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a key regulator of mitochondrial biogenesis.

In animal research models, SLU-PP-332 has been explored for its potential to enhance exercise endurance and promote more efficient use of energy substrates.

It has been described in early-stage investigations as a non-hormonal metabolic modulator, making it distinct from classical anabolic agents.

Key Features:

💊 100 × 250 mg research-grade tablets

🔬 ≥99% purity (independently lab-tested)

⚖️ Precisely dosed for reproducible experimental design

📦 Supplied in secure, tamper-evident packaging

For research purposes only

Reviews

There are no reviews yet.

Be the first to review “Genetiq SLU-PP-332”

Your email address will not be published. Required fields are marked *

FAQs

Q: What are the possible side effects of VLS Retatrutide?
Common Side Effects:
1. Gastrointestinal Issues:
  • ○ Nausea: A common side effect, especially when starting the medication. This tends to improve over time as the body adjusts.
  • ○ Vomiting: Some people may experience vomiting, particularly during the initial stages of treatment.
  • ○ Diarrhea or Constipation: These can occur, with some people experiencing one more than the other.
  • ○ Abdominal Pain: Stomach discomfort or pain is also reported by some users.
 
2. These gastrointestinal side effects tend to be temporary but can be bothersome for some people. Doctors often recommend starting with a lower dose and gradually increasing to help minimize these symptoms.
 
3. Decreased Appetite
  • ○ While this is a desired effect for many, some people may experience it too strongly, leading to reduced food intake and potential issues like fatigue or weakness.
 
Less Common but Serious Side Effects:
1. Thyroid Tumors (Including Medullary Thyroid Cancer):
  • ○ Potential Risk: Similar to other GLP-1 receptor agonists, retatrutide may carry a risk of thyroid tumors, including medullary thyroid cancer (MTC), and a possible increased risk of developing certain types of thyroid conditions.
  • ○ Caution for those with a Family History: It is especially not recommended for people with a family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).
 
2. Pancreatitis (Inflammation of the Pancreas):
  • ○ Symptoms: Severe abdominal pain, nausea, and vomiting could indicate pancreatitis. If this happens, the drug should be discontinued immediately, and medical attention sought.
 
3. Kidney Problems:
  • ○ Dehydration Risk: If nausea, vomiting, or diarrhea are severe, dehydration could occur, which may lead to kidney problems. People with preexisting kidney conditions may need to be more cautious.
 
4. Low Blood Sugar (Hypoglycemia):
  • ○ This is more likely to occur if Retatrutide is used in combination with other diabetes medications that lower blood sugar, such as insulin or sulfonylureas.
  • ○ Symptoms: Shaking, sweating, dizziness, and confusion are signs of low blood sugar.
 
5. Allergic Reactions:
  • ○ Symptoms: Rash, itching, swelling, or difficulty breathing could indicate an allergic reaction. In severe cases, this could lead to anaphylaxis (a life-threatening reaction), though this is rare.
 
6. Gallbladder Problems:
  • ○ Gallstones: There is a potential risk of developing gallstones, which could lead to pain in the upper abdomen, nausea, and vomiting.
Q: How should I use VLS Retatrutide?
Use VLS Retatrutide exactly as your healthcare provider tells you to.
  • • VLS Retatrutide is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Do not inject VLS Retatrutide into a muscle (intramuscularly) or vein (intravenously).
  • • Use VLS Retatrutide 1 time each week, on the same day each week, at any time of the day.
  • • You may change the day of the week you use VLS Retatrutide as long as your last dose was given 2 or more days before.
  • • If you miss a dose of VLS Retatrutide, take the missed dose as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day.
  • • VLS Retatrutide may be taken with or without food.
  • • Do not mix insulin and VLS Retatrutide together in the same injection.
  • • You may give an injection of VLS Retatrutide and insulin in the same body area (such as your stomach area), but not right next to each other.
  • • Change (rotate) your injection site with each injection. Do not use the same site for each injection.
  • • Check your blood sugar as your healthcare provider tells you to.
  • • Stay on your prescribed diet and exercise program while using VLS Retatrutide.
  • • Talk to your healthcare provider about how to prevent, recognize and manage low blood sugar(hypoglycemia), high blood sugar (hyperglycemia), and problems you have because of your diabetes.
  • • Your healthcare provider will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.
  • • Do not share your VLS Retatrutide pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
  • • Your dose of VLS Retatrutide and other diabetes medicines may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, fever, trauma, infection, surgery or because of other medicines you take.
  • • If you take too much VLS Retatrutide, call your healthcare provider or go to the nearest hospital emergency room right away.
Q: When should I not use VLS Retatrutide?
Do not use VLS Retatrutide if:
  • • Risk of Thyroid Tumors: Like other GLP-1 receptor agonists, retatrutide could increase the risk of developing thyroid tumors, including medullary thyroid cancer. People with a family history of MTC or MEN 2 are generally advised not to use drugs in this class.
  • • Gastrointestinal Side Effects: Retatrutide, like other similar medications, may cause gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation. Those with severe gastrointestinal conditions (e.g., gastroparesis, bowel obstruction) might experience worsened symptoms or complications.
  • • Risk of Hypoglycemia: While retatrutide has shown potential for controlling blood sugar in Type 2 diabetes, it is not intended for use in Type 1 diabetes. The medication may cause blood sugar to drop too low in people with Type 1 diabetes, potentially leading to dangerous hypoglycemic episodes.

Related products

Home
Account
1
Search
Scroll to Top